Search Our Scientific Publications & Authors

Publications
find publications by category +
Translate page:

Case reports: chemoradiotherapy for locally advanced neuroendocrine carcinoma of the gallbladder.

Authors:
Yuma Takeda Noritoshi Kobayashi Takaomi Kessoku Naoki Okubo Akihiro Suzuki Motohiko Tokuhisa Haruo Miwa Naoko Udaka Yasushi Ichikawa

Clin J Gastroenterol 2022 Aug 2;15(4):803-808. Epub 2022 Jun 2.

Department of Oncology, Yokohama City University School of Medicine Graduate School of Medicine, Yokohama, Japan.

Neuroendocrine carcinoma (NEC) is a rare subtype of malignant gallbladder tumor. Although surgical resection is the only potentially curative therapy for gallbladder NEC, most cases are surgically unresectable because of advanced stage disease and/or biologically aggressive behavior. The standard palliative treatment for malignant gallbladder tumors is chemotherapy; however, the efficacy of chemoradiotherapy in the treatment of gallbladder tumors is controversial. Here, we report a case of gallbladder NEC that showed a durable response to chemoradiotherapy. A 68-year-old Japanese man presented with a huge gallbladder tumor with liver and duodenal invasion. Pathological findings revealed poorly differentiated NEC of the gallbladder. After seven cycles of chemotherapy comprising cisplatin and irinotecan, computed tomography (CT) revealed remarkable tumor shrinkage, but an enlarged portal lymph node. The patient was treated with 50.4 Gy in 28 fractions with two cycles of cisplatin and etoposide. After chemoradiotherapy, the enlarged lymph node also decreased in size. Maximum standardized uptake value of fluorodeoxyglucose-positron emission tomography/CT(FDG-PET/CT) changed from 8.2 to physiological accumulation. We defined this condition as a complete response on both enhanced CT and FDG-PET/CT; therefore, we did not perform systemic treatment and only observed his condition. This patient remained healthy with no recurrence at 3 years after chemoradiotherapy.

Download full-text PDF

 Source
http://dx.doi.org/10.1007/s12328-022-01645-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9334423PMC
August 2022

Publication Analysis

Top Keywords

neuroendocrine carcinoma
8
gallbladder nec
8
gallbladder tumors
8
malignant gallbladder
8
gallbladder tumor
8
lymph node
8
gallbladder
8
chemoradiotherapy
5
3 years chemoradiotherapy
4
chemoradiotherapy enlarged
4
chemoradiotherapy 68-year-old
4
68-year-old japanese
4
etoposide chemoradiotherapy
4
cisplatin etoposide
4
japanese man
4
cycles cisplatin
4
man presented
4
fractions cycles
4
response chemoradiotherapy
4
nec durable
4

Keyword Occurance

Similar Publications

Small cell neuroendocrine carcinoma of the cervix: Analysis of prognostic factors and patterns of metastasis.

Authors:
Sushmita Gordhandas Brooke A Schlappe Qin Zhou Alexia Iasonos Mario M Leitao Kay J Park Louise de Brot Kaled M Alektiar Paul J Sabbatini Carol A Aghajanian Claire Friedman Oliver Zivanovic Roisin E O'Cearbhaill

Gynecol Oncol Rep 2022 Oct 4;43:101058. Epub 2022 Aug 4.

Gynecologic Medical Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Objectives: To describe characteristics and outcomes of patients with small cell neuroendocrine carcinoma of the cervix (SCNCC) and determine the staging system most predictive of outcome-the two-tier (limited-stage [LS] vs. extensive-stage [ES]) or International Federation of Gynecology and Obstetrics (FIGO) staging system.

Methods: Patients with SCNCC evaluated at our institution from 1/1/1990-6/30/2021 were included. Read More

View Article and Full-Text PDF
October 2022
Similar Publications

Progressive neuroendocrine tumor of lung with combined categories in metastatic site: a case report.

Authors:
Ling Ai Jingyuan Li Ting Ye Wenjun Wang Yuying Li

Transl Cancer Res 2022 Jul;11(7):2438-2442

Department of Respiratory and Critical Care Medicine, The Affiliated Hospital of Southwest Medical University, Luzhou, China.

Background: Both large cell neuroendocrine carcinoma (LCNEC) and small cell lung carcinoma (SCLC) are high-grade neuroendocrine tumors of lung in classification. Combined LCNEC and combined SCLC may comprise up to 25% of the resected cases. However, co-existence of LCNEC and SCLC in lung accompanied with combined LCNEC in extrapulmonary metastatic sites is infrequent. Read More

View Article and Full-Text PDF
July 2022
Similar Publications

CLINICAL CASE OF NON-TYPICAL METASTASIS OF NEUROENDOCRINE LUNG CARCINOMA TO THE VASCULAR MEMBRANE OF THE EYE.

Authors:
L M Zakhartseva H E Chytaieva O V Artemov

Exp Oncol 2022 08;44(2):169-173

The Filatov Institute of Eye Diseases and Tissue Therapy of the National Academy of Medical Sciences of Ukraine, Odesa 65061, Ukraine.

Background: Metastases in eye structures are rare (1-5% cases at systemic spread of different malignancies, mainly breast and lung cancers). The prognosis is poor. The overall survival usually does not exceed 12 or even 6 months. Read More

View Article and Full-Text PDF
August 2022
Similar Publications

Molecular profiling of human non-small cell lung cancer by single-cell RNA-seq.

Authors:
Qingqing Li Rui Wang Zhenlin Yang Wen Li Jingwei Yang Zhijie Wang Hua Bai Yueli Cui Yanhua Tian Zixin Wu Yuqing Guo Jiachen Xu Lu Wen Jie He Fuchou Tang Jie Wang

Genome Med 2022 Aug 13;14(1):87. Epub 2022 Aug 13.

State Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.

Background: Lung cancer, one of the most common malignant tumors, exhibits high inter- and intra-tumor heterogeneity which contributes significantly to treatment resistance and failure. Single-cell RNA sequencing (scRNA-seq) has been widely used to dissect the cellular composition and characterize the molecular properties of cancer cells and their tumor microenvironment in lung cancer. However, the transcriptomic heterogeneity among various cancer cells in non-small cell lung cancer (NSCLC) warrants further illustration. Read More

View Article and Full-Text PDF
August 2022
Similar Publications

Average treatment effect of facility hepatopancreatobiliary cancer volume on survival of non-resected pancreatic adenocarcinoma.

Authors:
Mohamedraed Elshami Fasih A Ahmed Hanna Kakish Jonathan J Hue Richard S Hoehn Luke D Rothermel David Bajor Amr Mohamed Jennifer E Selfridge John B Ammori Jeffrey M Hardacre Jordan M Winter Lee M Ocuin

HPB (Oxford) 2022 Jul 19. Epub 2022 Jul 19.

Division of Surgical Oncology, Department of Surgery, University Hospitals Cleveland Medical Center, Cleveland, OH, USA. Electronic address:

Background: To examine the average treatment effect of hepato-pancreato-biliary (HPB) cancer volume on survival outcomes of patients with non-resected pancreatic adenocarcinoma (PDAC).

Methods: We queried the National Cancer Database (2004-2018) for patients with HPB malignancies (PDAC, pancreatic neuroendocrine neoplasms, hepatocellular carcinoma, biliary tract cancers). We determined the 25th, 50th, and 75th percentiles based on the total annual HPB volume. Read More

View Article and Full-Text PDF
July 2022
Similar Publications
}